Insights, challenges, and future directions in irinogenetics.
about
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokineticsChemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management.Novel systemic therapies for small cell lung cancerPharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 yearsInstitutional Profile: The University of California Pharmacogenomics Center: at the interface of genomics, biological mechanisms and drug therapyPrediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer.Association between UGT1A1*28 polymorphisms and clinical outcomes of irinotecan-based chemotherapies in colorectal cancer: a meta-analysis in Caucasians.Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancerMethylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer.Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan.Fasting protects against the side effects of irinotecan but preserves its anti-tumor effect in Apc15lox mutant mice.Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study.Fasting protects against the side effects of irinotecan treatment but does not affect anti-tumour activity in miceGenotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer.Prospective study of the UGT1A1*27 gene polymorphism during irinotecan therapy in patients with lung cancer: Results of Lung Oncology Group in Kyusyu (LOGIK1004B).Somatic pharmacogenomics in cancer.Pharmacogenetics of solid tumors: directed therapy in breast, lung, and colorectal cancer: a paper from the 2008 william beaumont hospital symposium on molecular pathology.Intestinal glucuronidation protects against chemotherapy-induced toxicity by irinotecan (CPT-11).Pharmacogenetic pathway analysis of irinotecan.Genetic tests and genomic biomarkers: regulation, qualification and validationGenotypes Affecting the Pharmacokinetics of Anticancer Drugs.An overview of the recent progress in irinotecan pharmacogenetics.Role of capecitabine and irinotecan combination therapy in advanced or metastatic gastric cancer.Challenges in SN38 drug delivery: current success and future directions.Relationship between UGT1A1*6/*28 gene polymorphisms and the efficacy and toxicity of irinotecan-based chemotherapySingle nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression.Association between mismatch repair gene and irinotecan-based chemotherapy in metastatic colon cancer.
P2860
Q24651239-AFD0F642-279F-454F-BA08-5DFA1BD75424Q30318822-59F80670-428C-4D31-B1A7-B806E1E03634Q33862245-F83BFBE0-A5CA-401C-9713-0476DA97ED7FQ34008793-07CB0516-EE05-4521-8ED0-DF5ED03E06A9Q34071773-531F222E-52CB-49A8-B73F-7EE52BDDC7C9Q34565071-02668CA0-68FB-456A-BF96-9CB4C2B0049AQ34629650-F7223893-BA3C-4912-BC92-48A37E9E6E36Q35008045-ECCB3FCD-7E8A-4B72-9A72-221F924E0C5AQ35108413-1F20A9BF-19EA-4B55-BC14-309C1312117EQ35623320-49909710-039E-4713-8F6C-D6A0570A2699Q36111221-5819FC26-B8F0-4B29-977D-E11F24D0950AQ36183857-CC06CEA6-3375-4DA7-9F77-77E56DB66499Q36510493-5F63B0D1-E6B3-4A3C-8555-3E3DDC697BC0Q36599618-8478F436-4915-4A30-9959-425949FDD51EQ36915163-96925C1F-D067-4A2E-9F70-3FA7FEE14127Q37060403-DB0B3DBA-BF08-4E56-B334-DD2165BF8706Q37235024-AC7B1B7D-17F4-4248-92F6-7CE5D2FCB2EEQ37312970-CFED6462-A65E-4DC9-BAA8-CEFC6DA2FB9EQ37340600-5C95E540-E7C7-4D18-8E1E-79C6E341363BQ37381224-03746782-C0DF-42F6-A8E1-7A5A3834DC5DQ37430324-9CBE7272-DDD6-4EAA-B84B-5E7538D7DAFBQ37685527-ACE92F03-7E3E-4EAF-BB66-6162DAB8646EQ37710511-6EE40B7E-069E-48E1-8D66-29B7328EC653Q37732285-85E339CA-6794-4B4C-9E8E-D2045DFD9BB7Q38553224-7A80E0EE-6A13-4E4E-B7EC-009EE77D6EC0Q40494116-3FF684B0-120A-41F9-9548-0516813079C0Q43288450-275CD734-F992-4462-8F97-B35700C83F4FQ53440447-253CC848-A607-40BC-8133-8AFCC8041DE1
P2860
Insights, challenges, and future directions in irinogenetics.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Insights, challenges, and future directions in irinogenetics.
@en
type
label
Insights, challenges, and future directions in irinogenetics.
@en
prefLabel
Insights, challenges, and future directions in irinogenetics.
@en
P1476
Insights, challenges, and future directions in irinogenetics.
@en
P2093
Federico Innocenti
Tae Won Kim
P304
P356
10.1097/FTD.0B013E318068623B
P577
2007-06-01T00:00:00Z